What is Floreo?
Based in Washington DC, Floreo, Inc. operates at the intersection of immersive technology and cognitive intervention. The company provides a specialized virtual reality platform designed to teach social, communication, and life skills to individuals with ASD. By utilizing a patented process that integrates software with VR headsets, Floreo delivers supervised, interactive, and real-world scenarios that facilitate critical skill acquisition in a controlled environment.
This technology serves as a vital tool for clinicians, educators, and families, addressing a significant gap in accessible, evidence-based behavioral health solutions. By digitizing complex social interactions, Floreo is effectively democratizing access to high-quality cognitive therapy, positioning itself as a leader in the burgeoning neurodiversity-focused health tech market.
How much funding has Floreo raised?
Floreo has raised a total of $10.3M across 3 funding rounds:
Debt
$150K
Debt
$156K
Series A
$10M
Debt (2020): $150K with participation from PPP
Debt (2021): $156K led by PPP
Series A (2022): $10M supported by The Autism Impact Fund, Felton Group, The Disability Opportunity Fund, and Tenfore Holdings
Key Investors in Floreo
The Autism Impact Fund
A healthcare technology and innovation firm focused on investing in behavioral health, mental health, and autism, dedicated to improving care accessibility and outcomes for neurodiverse individuals.
The Disability Opportunity Fund
A nationally certified CDFI that provides financial products and advisory services to improve the quality of life and build wealth for people with disabilities and their families.
Tenfore Holdings
A global investment firm specializing in growth-stage and middle-market investments, focusing on companies that drive innovation and resilience in sectors like personalized medicine and AI-powered analytics.
What's next for Floreo?
With the recent infusion of capital, Floreo is poised to deepen its research partnerships and enhance its software capabilities to address a broader spectrum of cognitive needs. The strategic focus will likely shift toward expanding the platform's content library and integrating advanced analytics to track patient outcomes more effectively. As the company scales, it will continue to leverage its unique position to bridge the gap between clinical research and practical, daily-life application for the neurodiverse community.
The involvement of specialized impact investors suggests a long-term commitment to building a sustainable, outcomes-based care ecosystem. Future milestones will likely include broader market penetration, potential integration with existing healthcare delivery systems, and the continued refinement of its VR-based therapeutic interventions to ensure they remain at the forefront of behavioral health innovation.
